Thomas E. Stinchcombe
About
Thomas E. Stinchcombe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Thomas E. Stinchcombe has authored 215 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Pulmonary and Respiratory Medicine, 147 papers in Oncology and 31 papers in Cancer Research. Recurrent topics in Thomas E. Stinchcombe's work include Lung Cancer Treatments and Mutations (150 papers), Lung Cancer Diagnosis and Treatment (81 papers) and Lung Cancer Research Studies (71 papers). Thomas E. Stinchcombe is often cited by papers focused on Lung Cancer Treatments and Mutations (150 papers), Lung Cancer Diagnosis and Treatment (81 papers) and Lung Cancer Research Studies (71 papers). Thomas E. Stinchcombe collaborates with scholars based in United States, Canada and Hong Kong. Thomas E. Stinchcombe's co-authors include Mark A. Socinski, Patrick J. Roberts, Everett E. Vokes, Dominic T. Moore, Carrie B. Lee, Julian Rosenman, Vinicius Ernani, Xiaofei Wang, Karen Kelly and Channing J. Der and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
In The Last Decade
Thomas E. Stinchcombe
205 papers receiving 6.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas E. Stinchcombe United States | 41 | 3.9k | 3.7k | 1.7k | 824 | 664 | 215 | 6.9k | ||
| Mark Vincent Canada | 38 | 3.8k 1.0× | 3.7k 1.0× | 1.5k 0.9× | 723 0.9× | 656 1.0× | 171 | 6.5k | ||
| Wilfried Eberhardt Germany | 39 | 4.2k 1.1× | 5.3k 1.4× | 1.7k 1.0× | 892 1.1× | 559 0.8× | 239 | 7.6k | ||
| Sergei Tjulandin Russia | 34 | 5.3k 1.4× | 3.4k 0.9× | 1.4k 0.8× | 1.5k 1.8× | 1.5k 2.3× | 175 | 8.6k | ||
| Philip Bonomi United States | 42 | 4.9k 1.3× | 4.4k 1.2× | 2.1k 1.2× | 978 1.2× | 648 1.0× | 241 | 8.0k | ||
| Carla M.L. van Herpen Netherlands | 44 | 3.6k 0.9× | 1.9k 0.5× | 1.9k 1.1× | 707 0.9× | 1.1k 1.7× | 225 | 6.6k | ||
| Shenghui Tang United States | 39 | 2.9k 0.8× | 1.8k 0.5× | 1.2k 0.7× | 855 1.0× | 448 0.7× | 116 | 5.3k | ||
| Denis Soulières Canada | 41 | 3.9k 1.0× | 3.3k 0.9× | 1.9k 1.1× | 946 1.1× | 1.5k 2.3× | 258 | 7.5k | ||
| Daniel Betticher Switzerland | 38 | 2.4k 0.6× | 2.2k 0.6× | 1.7k 1.0× | 850 1.0× | 402 0.6× | 154 | 5.5k | ||
| Eleni Efstathiou United States | 41 | 2.4k 0.6× | 4.7k 1.3× | 2.0k 1.2× | 1.7k 2.1× | 615 0.9× | 203 | 7.4k | ||
| Rogério Lilenbaum United States | 33 | 5.6k 1.5× | 5.5k 1.5× | 2.1k 1.2× | 1.2k 1.5× | 473 0.7× | 105 | 8.4k |
Countries citing papers authored by Thomas E. Stinchcombe
Since
Specialization
Citations
This map shows the geographic impact of Thomas E. Stinchcombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Stinchcombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Stinchcombe more than expected).
Fields of papers citing papers by Thomas E. Stinchcombe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas E. Stinchcombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Stinchcombe. The network helps show where Thomas E. Stinchcombe may publish in the future.
Co-authorship network of co-authors of Thomas E. Stinchcombe
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Stinchcombe. A scholar is included among the top collaborators of Thomas E. Stinchcombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Stinchcombe. Thomas E. Stinchcombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Clarke, Jeffrey, George R. Simon, Hirva Mamdani, et al.. (2025). Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nature Communications. 16(1). 93–93.
2.
Ready, Neal, et al.. (2025). 261TiP: A single arm phase II study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor, cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer (TOP2201). Journal of Thoracic Oncology. 20(3). S162–S162.
3.
Wang, Xiaofei, et al.. (2025). Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020. JTO Clinical and Research Reports. 6(3). 100794–100794.
4.
Gerber, David E., Tanushree Prasad, Song Zhang, et al.. (2025). Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials. Clinical Cancer Research. 31(6). 1103–1108.
5.
Wood, C. G., Jacob M. Kaufman, Jeffrey Crawford, et al.. (2025). Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis. Journal for ImmunoTherapy of Cancer. 13(2). e010395–e010395.
6.
Li, Feng, Christopher M. Straus, Hedy L. Kindler, et al.. (2024). Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance). Journal of Imaging Informatics in Medicine. 38(2). 967–978.
7.
Ganti, Apar Kishor, Briant Fruth, Andreas Rimner, et al.. (2024). Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 131(1). e35663–e35663.
8.
Wang, X., Erin M. Bertino, Scott Antonia, et al.. (2023). A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open. 8(2). 101183–101183.
9.
Zhang, Siqi, Jianrong Zhang, Sida Liu, et al.. (2023). Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019). JCO Oncology Practice. 19(11). 1058–1068.
10.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973.
11.
Sands, Jacob, Sumithra J. Mandrekar, David Kozono, et al.. (2021). Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO). Immunotherapy. 13(9). 727–734.
12.
Ramalingam, Suresh S., Mark M. Awad, Afshin Dowlati, et al.. (2021). JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer. 128(1). 65–74.
13.
Bertino, Erin M., Ryan D. Gentzler, Jill Kolesar, et al.. (2020). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research. 27(6). 1604–1611.
14.
Zhao, Yu, Dongfang Tang, Sen Yang, et al.. (2020). Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non–Small Cell Lung Cancer Survival. Cancer Epidemiology Biomarkers & Prevention. 29(8). 1679–1688.
15.
Rich, Thereasa A., Karen L. Reckamp, Young Kwang Chae, et al.. (2019). Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research. 25(19). 5832–5842.
16.
Schild, Steven E., Thomas E. Stinchcombe, Everett E. Vokes, et al.. (2018). Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(2). 298–303.
17.
Stinchcombe, Thomas E., David Kozono, Joseph K. Salama, et al.. (2017). MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S1874–S1874.
18.
Dees, Elizabeth Claire, Roger B. Cohen, Margaret von Mehren, et al.. (2012). Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research. 18(17). 4775–4784.
19.
Stinchcombe, Thomas E., Jeffrey A. Bogart, Dennis A. Wigle, & Ramaswamy Govindan. (2010). Annual Review of Advances in Lung Cancer Clinical Research: A Report for the Year 2009. Journal of Thoracic Oncology. 5(7). 935–939.
20.
Stinchcombe, Thomas E., Mark A. Socinski, Christine M. Walko, et al.. (2007). Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 60(5). 759–766.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark Vincent Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Sergei Tjulandin Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Carla M.L. van Herpen Breakdown of academic impact, for papers by Shenghui Tang Breakdown of academic impact, for papers by Denis Soulières Breakdown of academic impact, for papers by Daniel Betticher Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Rogério Lilenbaum